Clinical Trials | April 30, 2026
Pfizer drug delivers breakthrough in late-stage blood cancer trial
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
